Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
ImmunoCellular Therapeutics (IMUC) Tops Q2 EPS by 1c
-
ImmunoCellular Therapeutics Announces Second Quarter 2016 Financial Results
-
ImmunoCellular Therapeutics (IMUC) Prices 47M Share Stock Offering for Proceeds of $7.4M
-
ImmunoCellular Therapeutics Announces Pricing of $7.4 Million Public Offering
-
Maxim Group's Jason Kolbert and Jason McCarthy Interviewed by The Life Sciences Report
-
ImmunoCellular (IMUC) Bullish View Reiterated at Maxim Group Amid ICT-107 Agreement
-
Maxim Group Maintains Bullish Stance on ImmunoCellular (IMUC) Following Review of SNO Data and Plans for Phase III
-
Pre-Open Stock Movers 9/24: (LPCN) (MACK) (ACOR) Higher; (ECTE) (ATOS) (GTI) Lower (more...)
-
Maxim Group Sees More than 500% Upside in Agenus (AGEN) Amid Results
-
Unusual 11 Mid-Day Movers 09/06: (RDN) (NAV) (MW) Higher; (OCZ) (FCEL) (PAY) Lower
-
Notable Analyst Rating Changes 09/06: (AKS) (ATVI) (GOLD) Upgraded; (NOK) (CLF) (OCZ) Downgraded
-
ImmunoCellular Therapeutics (IMUC) Ramps on New Buy Rating

